Danaher Co. (NYSE:DHR) Stock Position Increased by ORG Partners LLC

ORG Partners LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 1,212.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,770 shares of the conglomerate’s stock after buying an additional 2,559 shares during the period. ORG Partners LLC’s holdings in Danaher were worth $636,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the third quarter worth approximately $50,000. Darwin Wealth Management LLC acquired a new position in Danaher in the third quarter worth approximately $55,000. Finally, Modus Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter valued at $56,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $235.08 on Friday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The stock’s 50-day moving average is $235.67 and its two-hundred day moving average is $253.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market cap of $169.79 billion, a P/E ratio of 44.86, a PEG ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 earnings per share. Analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Raymond James cut their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.